Effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia

Effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN84216587

Enrollment

256

Registered

2010-04-07

Start date

2010-09-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Mental and Behavioural Disorders Schizophrenia

Interventions

Patients in the experimental group will receive BPT which will be delivered in groups of 8 patients and 20 sessions over a 10-week period. Each session will take 90 minutes. BPT is manualised with the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 65 years, either sex 2. An established diagnoses of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) 3. Having had symptoms of schizophrenia for at least 6 months 4. Scores of greater than 18 on the subscale negative symptoms of the Positive and Negative Syndrome Scale (PANSS) 5. Willingness to participate in groups for BPT or physical activity (PA) 6. Ability to give written informed consent

Exclusion criteria

Exclusion criteria: 1. Severe physical disability preventing patients from participating in groups for BPT or PA 2. Insufficient command of English so that outcomes cannot be reasonably assessed in English 3. A physical condition that makes participation in either BPT or the PA control group impossible or potentially harmful

Design outcomes

Primary

Measure	Time frame
Level of negative symptoms as assessed on the Positive and Negative Symptom Scale of Schizophrenia (PANSS). All outcomes will be measured at pre-treatment baseline, at the end of treatment and again 6 months after treatment.	—

Secondary

Measure	Time frame
All outcomes will be measured at pre-treatment baseline, at the end of treatment and again 6 months after treatment: 1. Levels of general psychopathology and positive symptoms (PANSS) 2. Subjective quality of life (Manchester Short Assessment of Quality of Life) 3. Extrapyramidal symptoms (Simpson-Angus Scale) 4. Treatment satisfaction (Client Satisfaction Questionnaire) 5. Objective social situation (SIX), which combines objective indicators of independent accommodation, employment and having a partner/friend 6. Instrumental Activities of Daily Living Scale (IADL)	—

Measure

Time frame

All outcomes will be measured at pre-treatment baseline, at the end of treatment and again 6 months after treatment: 1. Levels of general psychopathology and positive symptoms (PANSS) 2. Subjective quality of life (Manchester Short Assessment of Quality of Life) 3. Extrapyramidal symptoms (Simpson-Angus Scale) 4. Treatment satisfaction (Client Satisfaction Questionnaire) 5. Objective social situation (SIX), which combines objective indicators of independent accommodation, employment and having a partner/friend 6. Instrumental Activities of Daily Living Scale (IADL)

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 24, 2026